EU regulators recommend approving AstraZeneca's Covid-19 drug

European Medicines Agency (EMA)­, the European Union's drug regulator, has recently said that it is suggesting that an antibody medication established by AstraZeneca should be approved to help some people vulnerable to the coronavirus from getting sick.

EMA stated that it recommends the new drug, sold as Evusheld, should be offered to people aged 12 years and over before being exposed to COVID-19 to prevent future infections.

Previously, the drugs were cleared in December by the US Food and Drug Administration for people with severe health allergies or problems who are not able to get adequate protection from vaccination. Last week Britain also authorized Evusheld.

As per the agency, when the antibodies in Evusheld get attached to the spike protein, the virus will not be able to enter the cells to multiply and cannot cause COVID-19 infection.

The agency had the assessed data on the drug from around 5,000 people and found that Evusheld lowers the risk of infection by 77%, with protection predictable to last at least six months.

According to EMA, the side effects of the drug are mostly mild, with only some people complaining about reactions at the site where the drug is injected. The agency noted that the research was done before the rise of the enormously infectious omicron variant and said that it was assessing data to determine whether a different dose might be needed.

Moreover, even though the antibody drugs have been a regular treatment for treating COVID-19 infections for more than a year now, AstraZeneca antibody-drug is the very first expected for longstanding prevention against the COVID-19 contamination, rather than a temporary treatment.

People who could benefit from this drug include organ transplant recipients, cancer patients, and people taking immune-suppressing drugs for rheumatoid arthritis disease.

Source Credit -